Compounds > mk 0663
Page last updated: 2024-09-03

mk 0663 and papaverine

mk 0663 has been researched along with papaverine in 3 studies

Compound Research Comparison

Studies
(mk 0663)		Trials
(mk 0663)		Recent Studies (post-2010)
(mk 0663)		Studies
(papaverine)		Trials
(papaverine)		Recent Studies (post-2010) (papaverine)
5491732656,027305355

Protein Interaction Comparison

ProteinTaxonomymk 0663 (IC50)papaverine (IC50)
Chain A, cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10ARattus norvegicus (Norway rat)0.076
cGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)2.3
cGMP-specific 3',5'-cyclic phosphodiesteraseHomo sapiens (human)8.8
3',5'-cyclic-AMP phosphodiesterase Sus scrofa (pig)1.7
Bile salt export pumpHomo sapiens (human)10
cAMP-specific 3',5'-cyclic phosphodiesterase 4AHomo sapiens (human)1.6
Cytochrome P450 2C19Homo sapiens (human)0.762
Serine hydroxymethyltransferase, mitochondrialHomo sapiens (human)2.6915
Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1AHomo sapiens (human)9
Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1BHomo sapiens (human)9
cAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)1.4
Potassium voltage-gated channel subfamily H member 2Homo sapiens (human)7.2444
cGMP-inhibited 3',5'-cyclic phosphodiesterase BHomo sapiens (human)1.03
Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1CHomo sapiens (human)9
cGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)0.697
cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A Rattus norvegicus (Norway rat)0.036
Phosphodiesterase Sus scrofa (pig)0.62
cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10AHomo sapiens (human)0.07

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (33.33)29.6817
2010's2 (66.67)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Lombardo, F; Obach, RS; Waters, NJ1
Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ1
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ1

Other Studies

3 other study(ies) available for mk 0663 and papaverine

ArticleYear
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
    Drug metabolism and disposition: the biological fate of chemicals, 2008, Volume: 36, Issue:7

    Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding

2008
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
    Toxicological sciences : an official journal of the Society of Toxicology, 2010, Volume: 118, Issue:2

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics

2010
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
    Toxicological sciences : an official journal of the Society of Toxicology, 2013, Volume: 136, Issue:1

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests

2013